Novanta Completes Acquisition of Riverpoint Medical
Novanta Inc. (Nasdaq: NOVT) said it has completed its acquisition of Riverpoint Medical from Arlington Capital Partners. Novanta expects the deal to double recurring medical consumables revenue to about $300 million, raise medical end-market exposure to 60%, deliver high single-digit ROIC by year three, and add $0.18 to $0.25 of adjusted EPS in 2027.
How this was made
The 30-second read
Why it matters
Completion reduces deal overhang and shifts focus to integration execution. The company provides quantified targets (recurring medical consumables revenue to roughly $300 million, medical end-market exposure to 60%, ROIC by year three, and 2027 adjusted EPS contribution) while deferring 2026 impact specifics to the Q2 earnings call.
Market read
Traders can update models for NOVT based on deal-completion confirmation and the stated 2027 adjusted EPS accretion range, with the next catalyst being the Q2 call’s 2026 impact details.
What to watch
Investors may discount the EPS range until the company provides the specific 2026 financial impact and any updated assumptions on integration costs, amortization, and purchase accounting.
Background
Novanta announced and now completed the acquisition of Riverpoint Medical from Arlington Capital Partners, positioning Riverpoint as a high-growth minimally invasive surgical consumables business.
Ticker impact
Novanta completed its acquisition of Riverpoint Medical and guided 2027 adjusted EPS contribution of $0.18 to $0.25.
Near-term upside bias as investors price in accretion and medical consumables mix shift; volatility likely around integration and 2026 impact details on the Q2 call.
The article is a primary disclosure of a completed acquisition with specific financial expectations (recurring revenue target, ROIC by year three, EPS contribution in 2027) and a stated plan to provide 2026 financial impact later.
Market effects
Reinforces consolidation and growth-through-consumables strategy in minimally invasive surgical products, potentially raising competitive expectations for OEM-linked consumables platforms.
Limited direct regional read-through beyond strengthening FDA-registered manufacturing footprint referenced by the company.
Moderate global relevance via medical end-market exposure increase and recurring consumables revenue expansion.
Counterpoint
The deal’s accretion and ROIC targets may be optimistic if integration, OEM customer retention, or margin realization lags, especially given the lack of purchase price allocation detail in the release.
Key entities
- public_companyNovanta Inc.
Acquirer; completed the Riverpoint Medical acquisition and provided deal accretion and 2027 adjusted EPS contribution guidance.
- businessRiverpoint Medical
Target; minimally invasive surgical consumables provider with advanced surgical fibers and related technologies.
- private_firmArlington Capital Partners
Seller of Riverpoint Medical.
